Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages

Does cardiovascular-kidney-metabolic (CKM) stage modify the effects of the nonsteroidal mineralocorticoid receptor antagonist finerenone?In this post hoc analysis of 2 phase 3 clinical trials that included 12 990 participants, 3864 (30%) were classified as CKM stage 2, 3275 stage 3 (25%), and 5851 stage 4 (45%). Finerenone consistently reduced cardiovascular and kidney events, irrespective of baseline CKM stage; finerenone treatment was additionally associated with a higher likelihood of CKM syndrome regression, and a lower likelihood of progression, over time.In this study, finerenone reduced risks of cardiovascular and kidney events across CKM stages and had favorable effects on CKM syndrome evolution.

Corresponding Author: Muthiah Vaduganathan, MD, MPH, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (mvaduganathan@bwh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.